Arcturus Therapeutics Holdings Inc. (ARCT) fell 55.79% to trade at $10.26, down $12.90, after reporting interim results from its Phase 2 trial of ARCT-032, an inhaled mRNA therapy for cystic fibrosis.
The trial showed the therapy was generally safe and well tolerated, and imaging data revealed mucus-plug reduction in four of six participants; however, lung-function improvements did not meet expectations, contributing to investor disappointment.
On Wednesday, ARCT opened at $23.15, hit a high of $23.90, and a low of $9.85, compared to a previous close of $23.16 on the NASDAQ. Trading volume surged to approximately 50 million shares, far exceeding the average of ~0.7 million. The stock's 52-week range is $8.04 - $37.40.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.